// App-Quantinova.ai

AB0820 : COMPARATIVE EFFICACY OF GUSELKUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

Researchers

Presenter

  • I. Mcinnes

Principal Investigators

  • P. J. Mease

  • K. Eaton

  • A. Schubert

  • S. Peterson

  • T. Disher

  • W. Noel

  • H. Fareen

  • C. Karyekar

  • S. Van Sanden

  • C. T. Ritchlin

  • W. H. Boehncke

Medical Centers

  • University of Glasgow, Glasgow, United Kingdom

  • 2Swedish Medical Center/Providence St. Joseph Health and University of Washington, Rheumatology, Seattle, Washington, United States of America

  • EVERSANA, Burlington, ON, Canada

  • Janssen-Cilag, Warsaw, Poland

  • , Janssen Global Services, LLC, Horsham, PA, United States of America

  • EVERSANA, Sydney, Canada

  • Janssen Pharmaceutica NV, Beerse, Belgium

  • Janssen Cilag, High Wycombe, United Kingdom

  • University of Rochester, Rochester, NY, United States

  • Geneva University Hospitals, Geneva, Switzerland

Locations

  • United Kingdom

  • United States

  • Canada

  • Poland

  • Belgium

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Dermatology

  • Musculoskeletal

  • Autoimmune (AI)

Disease

  • Psoriatic arthritis

  • Dactylitis

  • Inflammatory Arthritis

  • Psoriasis

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • guselkumab (IV)

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • N/A

Sponsors

  • Bristol-Myer Squibb

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved